‘Vaccine AstraZeneca less effective against South African virus’

The coronavaccin developed by AstraZeneca and the University of Oxford seems to offer less protection against mild and moderate symptoms of disease caused by the South African virus variant. Thats what The Financial Times writes. The newspaper refers to a study that will be published on Monday.

The pharmaceutical company says in a reaction that it was a small-scale test in the phase I/II. Indeed, the initial data indicated a limited effectiveness against mild disease, in particular due to the B.1.351 variant from South Africa. Efficacy against serious complaints that could lead to hospitalization could not be properly verified because the vaccinated subjects were mainly young and healthy adults.

AstraZeneca believes that the vaccine can provide protection against severe signs of disease because the immune response generated is similar to that of other COVID-19 vaccines, with proven effectiveness against heavier cases. According to the spokesman, this is certainly true if the interval between dosages is optimized to 8 to 12 weeks.

British mutation

Oxford scientists announced on Friday that the vaccine is as effective against the British mutation as it is against the original virus strain for which it was made. Their research results have not yet been reviewed by other experts. Oxford argues that vaccinated people who become infected carry fewer virus particles and get rid of them faster